UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2020

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

001-39567

(Commission File Number)

(State or Other Jurisdiction of Incorporation) 0 Arsenal Way, Suite 20 Watertown MA

Delaware

490 Arsenal Way, Suite 200 Watertown, MA (Address of Principal Executive Offices) 47-5617627 (IRS Employer Identification No.)

> 02472 (Zip Code)

Registrant's Telephone Number, Including Area Code: (617) 231-0700

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	CCCC	The Nasdaq Global Select Market

Turk

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On November 18, 2020, C4 Therapeutics, Inc. (the "Company") posted an investor presentation to its website at https://ir.c4therapeutics.com/events-presentations. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number

Description 99.1 Investor Presentation of the Company dated November 2020 (furnished herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

C4 Therapeutics, Inc.

Date: November 19, 2020

By: /s/ Andrew J. Hirsch Andrew J. Hirsch President and Chief Executive Officer









Corporate Presentation

November 2020



© 2020 C4 Therapeutics, Inc.

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and overseas, including, without limitation, C4 THERAPEUTICS, TORPEDO, BIDAC and MONODAC. All trademarks or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols $^{\circ}$ and m , but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.




C4 Therapeutics' Vision

Pioneering protein degradation as a new class of medicine by:

- Harnessing the body's natural cellular quality control mechanisms to target and destroy disease-causing proteins
- Perfecting a novel discovery and validation platform to rapidly and cost-effectively bring transformative medicines to patients




Investment Highlights




Degradation Leverages Natural Cellular Machinery to Target Diseases

Protein degraders harness the body's natural protein degradation machinery to target and destroy selected disease-causing proteins



Targeted Protein Degradation: An Integrated Approach for a Novel Modality

C4 Therapeutics maintains a broad focus on **overall catalytic degradation** rather than a specific part of the degradation cycle, **providing opportunities to drug the undruggable**






© 2020 C4 THERAPEUTICS, INC.

Overview of Targeted Protein Degraders

- Degraders control protein levels by leveraging the cell's natural "quality control" or "protein recycling" system through a process called ubiquitination
- Degraders induce targeted destruction of harmful or disease-causing proteins by tagging them for ubiquitination
- Tagged proteins are subsequently degraded by the proteasome
- A single degrader molecule participates in multiple rounds of targeted protein target degradation, maximizing both potency and efficiency

Protein Degradation is Fundamentally Different than Protein Inhibition

Protein degraders allow for a more potent and durable pharmacological response at lower overall exposure levels than inhibitors





© 2020 C4 THERAPEUTICS, INC.

Key Advantages of Efficient Catalysis

1. Improved Potency

Degraders are recycled and can engage multiple target proteins, resulting in improved activity against resistant proteins, greater depth of effect, and more durable outcomes

2. Fast Response

Rapid degradation of target leads to strong and prolonged biological response

3. High Selectivity


Degraders can leverage multiple layers of selectivity in cellular machinery

4. Expansive Target Landscape


Degraders can be designed to bind to any part of the protein and are not limited to the active site, like most small molecule inhibitors, which means that previously undruggable targets may be degraded

TORPEDO Platform: Robust Drug Discovery and Higher Confidence in Clinical Outcomes

Design




- Computational method incorporates experimental data to identify top models
- Atomic-level degrader design utilized to improve selectivity and potency



Analyze

- Cellular degradation data fitted using an enzymology framework
- Key parameters describe intrinsic degradation activity

Predict




- Universal modeling framework merges degradation activity with degrader exposure
- Robust predictions of depth and duration of *in vivo* target degradation at any dose

8

Rapid delivery of potent drug candidates through informed and efficient drug discovery



PK/PD Models Provide Robust Predictions Across the Lead Programs



TORPEDO is Based on a Deep Focus on Cereblon, Rather than the Entire Set of Available Ligases

Our TORPEDO platform has a **diverse and rich toolkit of novel, structurally distinct Cereblon binders** – small molecules that are suitable for clinical targeted protein degradation

Cereblon E3 Ligase	*** ***** *****	Cereblon , harnessed by lenalidomide, or IMiDs, is the only clinically validated ligase for targeted protein degradation
Coldra	Ø	Cereblon is expressed in all tissues and in all cellular compartments
		Invested heavily in rich toolkit of intellectual property with 14 structurally distinct Cereblon binders, giving C4T a competitive advantage
		C4T's binders enable drug discovery with enhanced oral bioavailability, solubility, permeability and stability
E E		All projects benefit from desirable properties offered by C4T's Cereblon binders
C4 Therapeutics		© 2020 C4 THERAPEUTICS, INC.

Robust Pipeline With Four Clinical Programs Anticipated By End of 2022

Target/Product		Degrader	Route of	Phase of Development					
Designation	Indication(s)	Туре	Administration	Discovery	Pre-Clinical	Phase 1	Phase 2	Phase 3	Ownership
IKZF1/3 CFT7455	Hematologic malignancies	MonoDAC	Oral						c4 Therapeutics
BRD9 CFT8634	Sarcoma	BiDAC	Oral						C4 Therapeutics
BRAF V600E	Genetically defined resistant solid tumors	BIDAC	Oral						C4 Therapeutics
RET	Genetically defined resistant solid tumors	BiDAC	Oral						C4 Therapeutics


Target selection emphasizes target validated, mitigated tolerability risks and opportunity for accelerated approval



CFT7455: Clear Unmet Need Combined with Compelling Development Opportunity

	IKZF1/3 Mutations	IKZF1 and IKZF3 are central to lymphoid cell differentiation and maintenance			
Strong Mechanistic Rationale	 Multiple myeloma (MM) and Non-Hodgkin lymphomas (NHLs) are dependent on IKZF1/3 				
Clear Unmet Need	 IKZF1/3 degraders are the backbone of MM treatment Relapsed / refractory MM remains an unmet medical need Approved IMiDs have limited activity in NHL, including mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL) 	G-loop (12)			
Defined Patient Population	 MM: ~32,270 cases/year (US); median 5-year overall survival (OS): 53.9% NHL: ~77,240 cases/year (US) PTCL: ~4% of all NHLs (US); median 5-year OS: 20-32% 	CRBN Ligand Tri-Trp Pocket Potential Clinical Indications			
	- MCL: ~7% of all NHLs (US); median OS of 4-5 years	 Multiple myeloma Other B-cell lymphomas – MCL, diffuse large B-cellymphoma (DLBCL), and follicular lymphoma 			
Compelling Development Opportunity to expand i	Opportunity to expand into early lines of MM therapy	 PTCL represents unrealized path for development Additional indication line extension potential 			
Source: NIH SEER Database, P					


CFT7455 Is a Potent IKZF1/3 MonoDAC, as Demonstrated in Preclinical Studies




Catalytic activity results in potent degradation and activity



CFT7455: Potent Efficacy, In Vivo, with Complete Regressions as Single Agent in MM




Multiple Myeloma Xenograft Insensitive to Pomalidomide Responds to CFT7455







Proposed CFT7455 First-In-Human Trial Design Offers Potential for Accelerated Approval




- · Primary objectives are to characterize safety and tolerability and estimate anti-tumor activity, with key secondary objective to assess pharmacokinetics
- Trial design allows for three potential indications, each with opportunity for accelerated approval if expansion portions are successful
- Expansion stage doses will be at maximum tolerable dose (MTD) / recommended Phase 2 dose (RP2D) with different dosing strategy for MM vs. NHL due to historical lower tolerability for NHL and need for combination with dexamethasone in MM


28-day cycle / dose limiting toxicity (DLT) window
 Combination therapy cohorts will open once each CFT7455 dose level has been cleared for safety



BRD9 Degradation: Clear Clinical Opportunity




Robust, Dose-Dependent Response in Yamato Xenograft Model Achieved with CFT8634* at Tolerable Dose Levels



* CFT8634 is the purified enantiomer of CFT7503 (a racemic mixture) and is the drug candidate moving into clinical development




CFT8634 First-in-Human Protocol Concept Schema




C4 Therapeutics

BRAF Degrader to Overcome Liability of Approved BRAF Inhibitors



RET Degradation May Significantly Improve Activity of Best-In-Class RET Inhibitors



Potential for Multiple Near-term Milestones Across Lead Programs

Pro-Forma cash balance of \$390M as of 9/30/20 provides runway into H2 2023

IKZF1/3 (CFT7455)	□IND Submission	□Phase 1 Initiation	 Phase 1 Top-line Safety Data Phase 1 Top-line Efficacy Data Proof of Mechanism
BRD9 (CFT8634)	✓ IND Enabling Study Initiation	□IND Submission □Phase 1 Initiation	□Top-Line Safety Data
BRAF			□Phase 1 Initiation
RET			□Phase 1 Initiation

22



